Patient Guide: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 22 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06238843
Status: 🟢 Enrolling Now
Condition: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase: PHASE3

Where You Can Participate

This study is available at 22 locations across the country.

Top locations include:
  • • Beijing, Beijing Municipality
  • • Matsuyama, Ehime
  • • Ota-Shi, Gunma
  • • And 19 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma - Join Clinical Trial NCTNCT06238843

How to Join This Clinical Trial - NCTNCT06238843

Learn how to participate in this PHASE3 trial studying an investigational therapy for Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06238843 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 22 locations. Find a study site near you:

Clinical Research Site

Beijing, Beijing Municipality 100142 - China

Status: RECRUITING

Clinical Research Site

Matsuyama, Ehime 791-0280 - Japan

Status: RECRUITING

Clinical Research Site

Ota-Shi, Gunma 373-8550 - Japan

Status: RECRUITING

Clinical Research Site

Kure, Hirosima [Hiroshima] 737-0023 - Japan

Status: RECRUITING

Clinical Research Site

Sapporo, Hokkaido 006-8555 - Japan

Status: RECRUITING

Clinical Research Site

Fukuoka, Hukuoka [Fukuoka] 811-1395 - Japan

Status: RECRUITING

Clinical Research Site

Akashi, Hyōgo 673-8558 - Japan

Status: RECRUITING

Clinical Research Site

Kobe, Hyōgo 650-0047 - Japan

Status: RECRUITING

Clinical Research Site

Kawasaki, Kanagawa 216-8511 - Japan

Status: RECRUITING

Clinical Research Site

Yokohama, Kanagawa 232-0024 - Japan

Status: RECRUITING

And 12 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships